Navigation Links
The Quigley Corporation to Announce Second Quarter Results and Host Audio Web Cast
Date:7/30/2009

DOYLESTOWN, Pa., July 30 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com today announced it will issue its second quarter results before market open on Wednesday, August 5, 2009.

Ted Karkus, Chairman and CEO, will provide a Company overview including a review of recent activities and second quarter results on a conference call which will be web cast on The Quigley Corporation's web site, (www.quigleyco.com), at 10:00 AM (ET) that morning.

A replay of the conference call will be available for 30 days on the Company web site.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY) (http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries including Quigley Manufacturing Inc., which consists of an FDA approved facility to manufacture COLD-EEZE(R) lozenges and fulfill other contract manufacturing opportunities, and Quigley Pharma Inc., (http://www.QuigleyPharma.com), which conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

CONTACT:

    Ted Karkus                   Media                    Investor Relations
    Chairman of the Board, CEO   Karen Pineman            Carl Hymans
    The Quigley Corporation      G.S. Schwartz & Co.      G.S. Schwartz & Co.
    (215) 345-0919               212.725.4500             212.725.4500
                                 kpineman@schwartz.com    carlh@schwartz.com


'/>"/>
SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study
2. Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
3. Dr. Richard Rosenbloom Resumes Services To The Quigley Corporations Pharma Subsidiary
4. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
5. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
6. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
7. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
8. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
9. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
10. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
11. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... ... eve of Autism Awareness Month, representatives from Organic Consumers Association, National Health Freedom ... For Health Foundation, A Voice for Choice, Moms Across America, Freedom and Ethics ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... letter to President Trump expressing their support for an independent Vaccine Safety Commission. ... scientists and one medical journalist, will hold a press conference at 9:00 ...
(Date:3/29/2017)... NY (PRWEB) , ... March 29, 2017 , ... ... men’s and women’s professional squash, announced it has enlisted New York City-based sports ... The agency will develop and procure sponsorship opportunities for the Professional Squash Association ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Youth Futures International ... success and feedback from high school and college students who have participated in the ... July 7-23 and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org ...
(Date:3/29/2017)... Baton Rouge, Louisiana (PRWEB) , ... March 29, ... ... trademarked HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, ... campaign at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... PHILADELPHIA , March 30, 2017  Lannett Company, ... the company voluntarily made a $25 million payment against ... $25 million payment, combined with the $75 million payment ... us approximately $5.5 million in annualized cash interest expense, ... executive officer of Lannett.  "Our business is solid and ...
(Date:3/30/2017)... Research and Markets has announced the ... & Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, ... 2014 To 2025" report to their offering. ... The global ... 108.5 billion by 2025. Home-based dialysis ...
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
Breaking Medicine Technology: